Company ProfileWe are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
|Recent Press Releases||More >>|
|12/07/16||Ionis Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference|
|CARLSBAD, Calif., Dec. 7, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 14 in New York, NY.
A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis website. The replay will be available within 48 hours and will be archived for... || |
|11/15/16||Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx|
|Significant reductions in ANGPTL3, triglycerides and LDL cholesterol observed
Interim data presented during the Late Breaker Session at the American Heart Association Meeting
CAMBRIDGE, Mass., Nov. 15, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive results from an interim analysis of a Phase 1/2a study of IONIS-ANGPTL3-LRx. In this study, subjects with elevated triglycerides achieved subst... || |
|11/09/16||Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016|
|Conference Call Webcast Wednesday, November 9, 9:30 a.m. ET at www.ionispharma.com
CARLSBAD, Calif., Nov. 9, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported income from operations of $16.1 million and a loss from operations of $87.5 million for the three and nine months ended September 30, 2016, respectively. The Company also reported pro forma operating income of $33.7 million and a pro forma net operating loss (NOL) of $30.5 million, both excluding non-cash s... || |
|11/07/16||Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy|
|- Second Positive Phase 3 Study Provides Further Evidence of SPINRAZA's Efficacy and Favorable Safety Profile -
- Results Were Statistically Significant and Clinically Meaningful -
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 7, 2016-- Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) announced that SPINRAZATM (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at the interim analysis of CHERISH, th... |
|12/14/16 1:30 p.m. ET|
For more information requests, please visit our Information Request page.
If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.
Data provided by Nasdaq. Minimum 15 minutes delayed.